Pembrolizumab plus docetaxel for the treatment of recurrent metastatic head and neck cancer: A prospective phase I/II study

被引：1
|
作者：
Fuereder, T. [1 ]
Minichsdorfer, C. [1 ]
Mittlboeck, M. [2 ]
Wagner, C. [1 ]
Oberndorfer, F. [3 ]
Mullauer, L. [3 ]
Aretin, M-B. [4 ]
Czerny, C. [5 ]
Schwarz-Nemec, U. [5 ]
机构：
[1] Med Univ Vienna, Vienna Gen Hosp, Internal Med I, Vienna, Austria
[2] Med Univ Vienna, Vienna Gen Hosp, Ctr Med Stat Informat & Intelligent Syst, Vienna, Austria
[3] Med Univ Vienna, Vienna Gen Hosp, Pathol, Vienna, Austria
[4] Vienna Gen Hosp, Pharm, Vienna, Austria
[5] Med Univ Vienna, Vienna Gen Hosp, Biomed Imaging & Image Guided Therapy, Vienna, Austria
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.1036
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
921P
引用
收藏
页码：S665 / S665
页数：1
相关论文
共 50 条
  • [31] Results of a randomised phase II study comparing docetaxel to methotrexate in patients with recurrent head and neck cancer
    Guardiola, Emmanuel
    Peyrade, Frederic
    Chaigneau, Loic
    Cupissol, Didier
    Tchiknavorian, Xavier
    Bompas, Emmanuelle
    Madroszyk, Anne
    Ronchin, Patrik
    Schneider, Maurice
    Pivot, Xavier
    ANNALS OF ONCOLOGY, 2004, 15 : 138 - 138
  • [32] Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer
    Guardiola, E
    Peyrade, F
    Chaigneau, L
    Cupissol, D
    Tchiknavorian, X
    Bompas, E
    Madroszyk, A
    Ronchin, P
    Schneider, M
    Bleuze, JP
    Blay, JY
    Pivot, X
    EUROPEAN JOURNAL OF CANCER, 2004, 40 (14) : 2071 - 2076
  • [33] A phase II trial evaluating weekly docetaxel and capacitabine in patients with metastatic or advanced, locally, recurrent head and neck cancer
    Zhang, J.
    Lee, J. S.
    Urba, S.
    Worden, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [34] A phase 2 study of ipatasertib in combination with pembrolizumab for first-line treatment of recurrent or metastatic squamous cell cancer of the head and neck
    Thomas, Jacob Stephen
    Bruce, Justine Yang
    Li, Zujun
    Lorch, Jochen H.
    Phillips, Tanyanika
    Villaflor, Victoria
    Ruel, Christopher
    Palmer, Joycelynne
    Gutkind, J. Silvio
    Villalona-Calero, Miguel Angel
    Colevas, Alexander Dimitrios
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [35] DOCETAXEL PLUS CISPLATIN AS FIRST-LINE CHEMOTHERAPY IN PATIENTS WITH RECURRENT OR METASTATIC HEAD AND NECK CANCER
    Ohhara, Y.
    Nishimura, N.
    Nara, E.
    Nakano, K.
    Ueda, K.
    Sakajiri, S.
    Mishima, Y.
    Yokoyama, M.
    Terui, Y.
    Takahashi, S.
    Hatake, K.
    ANNALS OF ONCOLOGY, 2012, 23 : 125 - 125
  • [36] Afatinib and Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (ALPHA Study): A Phase II Study with Biomarker Analysis
    Kao, Hsiang-Fong
    Liao, Bin-Chi
    Huang, Yen-Lin
    Huang, Huai-Cheng
    Chen, Chun-Nan
    Chen, Tseng-Cheng
    Hong, Yuan-Jing
    Chan, Ching-Yi
    Chia, Jean-San
    Hong, Ruey-Long
    CLINICAL CANCER RESEARCH, 2022, 28 (08) : 1560 - 1571
  • [37] A phase II study of paclitaxel and cisplatin combination chemotherapy in recurrent or metastatic head and neck cancer
    Basaran, M
    Bavbek, SE
    Güllü, I
    Demirelli, F
    Sakar, B
    Tenekeci, N
    Altun, M
    Yalçin, S
    Onat, H
    JOURNAL OF CHEMOTHERAPY, 2002, 14 (02) : 207 - 213
  • [38] A phase II study evaluating axitinib in patients with unresectable, recurrent or metastatic head and neck cancer
    Paul L. Swiecicki
    Lili Zhao
    Emily Belile
    Assuntina G. Sacco
    Douglas B. Chepeha
    Irina Dobrosotskaya
    Matthew Spector
    Andrew Shuman
    Kelly Malloy
    Jeffrey Moyer
    Erin McKean
    Scott McLean
    Gregory T. Wolf
    Avraham Eisbruch
    Mark Prince
    Carol Bradford
    Thomas Carey
    Francis P. Worden
    Investigational New Drugs, 2015, 33 : 1248 - 1256
  • [39] A randomised, double-blind, placebo-controlled phase II study of setanaxib plus pembrolizumab for the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (rmSCCHN)
    Rullan, A.
    Adkins, D. R.
    Bossi, P.
    Cohen, E. E. W.
    Daste, A.
    Harrington, K. J.
    Le Tourneau, C.
    Licitra, L. F.
    Little, N.
    Morris, T.
    Ottensmeier, C. H. H.
    Reinwald, M.
    Rutkowski, T.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S863 - S864
  • [40] Phase I/II study of carboplatin with weekly ifostamide and docetaxel in recurrent or metastatic head and neck squamous cell cancers (HN-SCC).
    Chauhan, B
    Wanebo, H
    Rathore, R
    Chougule, P
    Kennedy, T
    Ready, N
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 513S - 513S
12345